scholarly journals Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients – Characterization of Injection Site Reactions and Flu-Like Symptoms in a Daily Practice Setting – Results from the Non-Interventional Study PERFECT

2021 ◽  
Vol Volume 15 ◽  
pp. 1091-1100
Author(s):  
Borries Kukowski ◽  
Karin Rehberg-Weber ◽  
Kirsi Taipale ◽  
Andreas Kowalik ◽  
Patrick Oschmann
Keyword(s):  
Multiple Sclerosis ◽  
Injection Site ◽  
Interferon Beta ◽  
Daily Practice ◽  
Practice Setting ◽  
Interventional Study ◽  
Injection Site Reactions ◽  
Multiple Sclerosis Patients

Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b

2007 ◽  
Vol 13 (9) ◽  
pp. 1153-1160 ◽  
Author(s):  
K. Baum ◽  
C. O'Leary ◽  
F. Coret Ferrer ◽  
E. Klimova ◽  
L. Prochazkova ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Injection Site ◽  
Interferon Beta ◽  
Injection Site Pain ◽  
Patient Acceptability ◽  
Injection Site Reactions ◽  
Relapsing Remitting ◽  
Multiple Sclerosis Patients ◽  
The Impact ◽  
Site Pain

This prospective, multicentre, international, observational, cohort study compared injection site pain (ISP) and injection site reactions (ISRS) between interferon beta-1b (IFNB-1b; Betaferon ®) 250 μg subcutaneously every other day and interferon beta-1a (IFNB-1a; Rebif®) 44 μg subcutaneously three times weekly in patients with relapsing-remitting MS. Patients started treatment within 3 months before recruitment and were on full dose of therapy at inclusion. Patients self-injected IFNB and self-assessed ISP for 15 consecutive injections immediately, 30 and 60 min after injection, using a visual analogue scale diary. Study staff assessed ISRS. Of 445 patients (valid cases), ~90% used autoinjectors. More patients were pain-free at all timepoints with IFNB-1b than with IFNB-1a (eg, 30 min: 42.6% versus 19.7%; P< 0.0001). The mean proportion of pain-free injections was greater for IFNB-1b (eg, 30 min: 79.0%) than for IFNB-1a (53.3%; P < 0.0001). The proportion of patients without ISRS was greater for IFNB-1b (second visit 51.8% versus 33.8%; P < 0.0001). Compared with IFNB-1a, more IFNB-1b patients either had no pain or their ISP had no influence on treatment satisfaction (76.9% versus 64.1%; P = 0.006). The impact on tolerability and patient acceptability of any new IFNB product formulations would, however, have to be evaluated in comparative studies. Multiple Sclerosis 2007; 13 : 1153—1160. http://msj.sagepub.com

scholarly journals A prospective study comparing injectable interferon beta-1a (Rebif 22-44), (Avonex 30) and 1b (Betaseron 250) injection site reaction in multiple sclerosis patients

10.19082/7574 ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 7574-7579
Author(s):  
Foziah Jabbar Alshamrani ◽  
Hind Alnajashi ◽  
Fahad Alkhamis ◽  
Ibrahim Alghanimi ◽  
Abdulla Alsulaiman ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Prospective Study ◽  
Injection Site ◽  
Interferon Beta ◽  
Injection Site Reaction ◽  
Site Reaction ◽  
Multiple Sclerosis Patients ◽  
A Prospective Study

Effects of Dose Titration on Tolerability and Efficacy of Interferon Beta-1b in People with Multiple Sclerosis

2005 ◽  
Vol 33 (3) ◽  
pp. 309-318 ◽  
Author(s):  
SJ Wroe
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Events ◽  
Injection Site ◽  
Interferon Beta ◽  
Dose Titration ◽  
Injection Site Reactions ◽  
Stage 4 ◽  
Relapsing Remitting ◽  
Set Up ◽  
Relapse Rates

Multiple sclerosis (MS) treatment with interferon beta is associated with well-known, easily managed adverse events, including influenza-like symptoms and injection-site reactions that decline over time. Initial dose titration has been shown to be one way of limiting these adverse events. Hence, a placebo-controlled, multicentre study of 98 patients was set up to explore whether a slower, four-stage, 4-week titration to a final dose of 250 μg subcutaneous interferon beta-1b might improve tolerability over a more rapid two-stage, 2-week titration in patients with relapsing-remitting MS. Frequency of adverse events was found to be similar between the two regimens: notably, no difference in the incidence of injection-site reactions, with a trend towards fewer influenza-like symptoms in the slow-titration group. Relative to placebo, significantly fewer patients receiving interferon beta-1b relapsed. This was more pronounced in the rapid-titration group than in the slow-titration group, showing that rapid and significant improvements in relapse rates were achieved within 90 days of starting interferon beta-1b. Although a rapid-titration regimen results in a quicker onset of clinical benefit, slow titration showed a non-significant trend towards reduced influenza-like symptoms.

Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis

2007 ◽  
Vol 14 (2) ◽  
pp. 259-261 ◽  
Author(s):  
G. Serarslan ◽  
EE Okuyucu ◽  
IM Melek ◽  
S. Hakverdi ◽  
T. Duman
Keyword(s):  
Multiple Sclerosis ◽  
Topical Corticosteroid ◽  
Injection Site ◽  
Positive Reaction ◽  
Interferon Beta ◽  
Maculopapular Rash ◽  
Histopathologic Examination ◽  
Prick Test ◽  
The Third ◽  
Injection Site Reactions

We describe a 41-year-old woman with multiple sclerosis, who presented erythematous maculopapular rash on the trunk and extremities after the second injection of interferon beta-1a. Histopathologic examination of the lesion revealed lymphocytic exocytosis and perivascular lymphocytic infiltrate in the dermis. Oral antihistamine and topical corticosteroid was started. After improvement of the lesions, the third injection was performed. However, the same reaction occurred. A prick test, which was performed 6 weeks after the eruption, also revealed positive reaction. Although injection-site reactions have been observed with interferon beta-1a, to our knowledge there have been no previous reports of interferon beta-1a-induced widespread cutaneous reaction. Multiple Sclerosis 2008; 14: 259—261. http://msj.sagepub.com

Interferon-beta injection site reactions in patients with multiple sclerosis

2018 ◽  
Vol 29 (8) ◽  
pp. 831-834 ◽  
Author(s):  
Martina Maurelli ◽  
Roberto Bergamaschi ◽  
Ambra Antonini ◽  
Maria Concetta Fargnoli ◽  
Elisa Puma ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Injection Site ◽  
Interferon Beta ◽  
Injection Site Reactions

Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a

2018 ◽  
Vol 17 (2) ◽  
pp. 113-118 ◽  
Author(s):  
Mohsen Ebrahimimonfared ◽  
Ali Ganji ◽  
Sara Zahedi ◽  
Parisa Nourbakhsh ◽  
Keyvan Ghasami ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
T Cells ◽  
Regulatory T Cells ◽  
Interferon Beta ◽  
Treg Cells ◽  
Relapsing Remitting ◽  
Multiple Sclerosis Patients ◽  
Control Study

Background: Regulatory T-Cells (Treg Cells), as one of the immune system components, have been highly effective in the autoimmune diseases prevention, particularly multiple sclerosis (MS). Cytokine-based therapies such as interferon beta-1a (IFN-β1a) is a common drug in MS treatment; however, its exact mechanisms are insufficiently described. Objective: Therefore, the goal of this study was to evaluate the in vivo impact of IFN-β1a on the Treg Cells in MS. Methods: In this case-control study, Treg Cells were analysed by flowcytometry in IFN-β1a-treated relapsing-remitting MS (RRMS) in comparison with new cases of MS and healthy subjects. Results: The frequency of Treg Cells in the IFN-β1a treated-RRMS was increased compared to the new MS cases (P < 0.05). Furthermore, the MFIs of the CD4 and CD25 in T-Cells were significantly reduced in new cases of MS and IFN-β1a-treated RRMS than the control subjects (P < 0.05). Additionally, the FoxP3 MFIs in CD4 + CD25 + T-Cells of IFN-β1a-treated RRMS were significantly lower than the new cases of MS. Conclusion: Overall, the present study indicated that IFN-β1a as an immunomodulatory drug led to an enhancement in Treg Cells population without CD4, CD25, and FoxP3 molecules upregulation in Treg Cells.

Sign in / Sign up

Export Citation Format

Share Document